Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

Affiliations

¹ Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
³ Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA. amer.zeidan@yale.edu.

Published Erratum

Tariq Kewan et al. Curr Hematol Malig Rep. 2024 Jun.

. 2024 Jun;19(3):151.

doi: 10.1007/s11899-024-00734-x.

¹ Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
³ Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Section of Hematology, Department of Internal Medicine, Yale School of Medicine, and Yale Comprehensive Cancer Center, Yale University, New Haven, CT, USA. amer.zeidan@yale.edu.

No abstract available

Erratum for

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.
Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Kewan T, et al. Curr Hematol Malig Rep. 2024 Jun;19(3):138-150. doi: 10.1007/s11899-024-00733-y. Epub 2024 Apr 18. Curr Hematol Malig Rep. 2024. PMID: 38632155 Review.